Cough News and Research RSS Feed - Cough News and Research

Cincinnati Children's doctors remind parents about the importance of immunizing kids before sending them to school

Cincinnati Children's doctors remind parents about the importance of immunizing kids before sending them to school

Doctors at Cincinnati Children's Hospital Medical Center want to remind parents about the importance of immunizing their children when preparing to send their children back to school. [More]
New diagnostic criteria can help distinguish malignant cancerous chest cavity masses from histoplasmosis

New diagnostic criteria can help distinguish malignant cancerous chest cavity masses from histoplasmosis

Researchers led by St. Jude Children's Research Hospital scientists have developed new diagnostic criteria to enable clinicians to distinguish malignant cancerous chest cavity masses from those caused by fungal histoplasmosis infection. [More]
UVA Children's Hospital finds potential cause of child paralysis outbreak

UVA Children's Hospital finds potential cause of child paralysis outbreak

A mysterious outbreak of child paralysis cases previously linked to enterovirus D68 may instead have another cause, doctors at the University of Virginia Children's Hospital are cautioning after determining that a stricken child appeared to be suffering from a different virus. [More]
FDA grants CLIA waiver for Alere i Strep A test

FDA grants CLIA waiver for Alere i Strep A test

Alere Inc., a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration has granted CLIA waiver for the Alere i Strep A test. The test, which was cleared for marketing by the FDA in April 2015, is the first molecular platform that detects Group A Streptococcus (GAS) bacteria in 8 minutes or less. [More]
Parents' views on safety and benefits of vaccines have shifted, finds new poll

Parents' views on safety and benefits of vaccines have shifted, finds new poll

Over the same time period that multiple outbreaks of measles and whooping cough made headlines around the country, parents' views on vaccines became more favorable, according to a new nationally-representative poll. [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris Pharma, Inc. today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare. [More]
Study: Acellular vaccines may have contributed to recent pertussis outbreak

Study: Acellular vaccines may have contributed to recent pertussis outbreak

Whooping cough has made an astonishing comeback, with 2012 seeing nearly 50,000 infections in the U.S. (the most since 1955), and a death rate in infants three times that of the rest of the population. [More]
Discovery provides basis for new pertussis treatments

Discovery provides basis for new pertussis treatments

The worldwide spreading of the whooping cough, also known as pertussis, has substantially increased since 2010. Researchers from the Biozentrum, University of Basel, have investigated structure and function of an important membrane protein of the bacterium causing pertussis. They discovered that the protein structure differs from a previously postulated model. [More]
Purdue University-led study could lead to better treatments for people infected with MERS virus

Purdue University-led study could lead to better treatments for people infected with MERS virus

A Purdue University-led team of researchers studying the Middle East Respiratory Syndrome, or MERS, have found molecules that shut down the activity of an essential enzyme in the virus and could lead the way to better treatments for those infected. [More]
New research could help reverse side effects of acetaminophen overdose

New research could help reverse side effects of acetaminophen overdose

New research could help reverse deadly side effects caused by excessive doses of the drug acetaminophen, the major ingredient in Tylenol and many other over-the-counter and prescription medicines. [More]

Helmholtz Zentrum München scientists investigating molecular causes of COPD

At present, there is a lack of effective treatments that target the causes of chronic obstructive pulmonary disease (COPD). Scientists of the Comprehensive Pneumology Center at Helmholtz Zentrum München are therefore investigating the molecular causes of COPD in order to intervene specifically. [More]
Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent. [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
Intermountain Healthcare participates in antibiotic stewardship forum at the White House

Intermountain Healthcare participates in antibiotic stewardship forum at the White House

Intermountain Healthcare is one of 150 organizations in the nation that was invited to the White House to help develop national policy to address the growing problem of the overuse of antibiotics. [More]
Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for Anthim® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness. [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

Actavis plc and its partner Perrigo Company plc announced today that Actavis has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in time for the cough/cold season to its retail and wholesale customers in the U.S. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® D tablets. [More]
Group Health Research Institute conducts first randomized trial to tackle vaccine hesitancy

Group Health Research Institute conducts first randomized trial to tackle vaccine hesitancy

Group Health Research Institute conducted the first randomized trial to test an intervention aimed at improving hesitancy about early childhood vaccines by working directly with doctors. Vax Northwest, a Washington state public-private partnership, developed the intervention. [More]
Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Advertisement
Advertisement